Tools   Select Another Resource Report Type

http://faculty.washington.edu/chudler/ehc.html

This web site focuses on neuroscience, the study of the nervous system. Links on this page are limited to those Dr. Chundler finds to be the most interesting and useful.

Proper citation: Eric H. Chundlers Links (RRID:SCR_008328) Copy   

•   Source: SciCrunch Registry

http://neuroscienceblueprint.nih.gov/

Collaborative framework that includes the NIH Office of the Director and the 14 NIH Institutes and Centers that support research on the nervous system. By pooling resources and expertise, the Blueprint identifies cross-cutting areas of research, and confronts challenges too large for any single Institute or Center. The Blueprint makes collaboration a day-to-day part of how the NIH does business in neuroscience, complementing the basic missions of Blueprint partners. During each fiscal year, the partners contribute a small percentage of their funds to a common pool. Since the Blueprint's inception in 2004, this pool has comprised less than 1 percent of the total neuroscience research budget of the partners. In 2009, the Blueprint Grand Challenges were launched to catalyze research with the potential to transform our basic understanding of the brain and our approaches to treating brain disorders. * The Human Connectome Project is an effort to map the connections within the healthy brain. It is expected to help answer questions about how genes influence brain connectivity, and how this in turn relates to mood, personality and behavior. The investigators will collect brain imaging data, plus genetic and behavioral data from 1,200 adults. They are working to optimize brain imaging techniques to see the brain's wiring in unprecedented detail. * The Grand Challenge on Pain supports research to understand the changes in the nervous system that cause acute, temporary pain to become chronic. The initiative is supporting multi-investigator projects to partner researchers in the pain field with researchers in the neuroplasticity field. * The Blueprint Neurotherapeutics Network is helping small labs develop new drugs for nervous system disorders. The Network provides research funding, plus access to millions of dollars worth of services and expertise to assist in every step of the drug development process, from laboratory studies to preparation for clinical trials. Project teams across the U.S. have received funding to pursue drugs for conditions from vision loss to neurodegenerative disease to depression. Since its inception in 2004, the Blueprint has supported the development of new resources, tools and opportunities for neuroscientists. For example, the Blueprint supports several training programs to help students pursue interdisciplinary areas of neuroscience, and to bring students from underrepresented groups into the neurosciences. The Blueprint also funds efforts to develop new approaches to teaching neuroscience through K-12 instruction, museum exhibits and web-based platforms. From fiscal years 2007 to 2009, the Blueprint focused on three major themes of neuroscience - neurodegeneration, neurodevelopment, and neuroplasticity. These efforts enabled unique funding opportunities and training programs, and helped establish new resources including the Blueprint Non-Human Primate Brain Atlas.

Proper citation: NIH Blueprint for Neuroscience Research (RRID:SCR_003670) Copy   

•   Source: SciCrunch Registry

http://www.animalgenome.org/pigs/nagrp.html

Database and resources on the pig genome.

Proper citation: U.S. Pig Genome Project (RRID:SCR_008151) Copy   

•   Source: SciCrunch Registry

http://csgr.pgml.uga.edu/

The objective of this project is to develop physical maps of the sorghum and rice genomes, based on BAC contigs that are cross-linked to each other and also to genetic maps and BAC islands for other large-genome crops and a library of ca. 50,000 expressed-sequence tags (EST''s) and corresponding cDNA clones, from diverse sorghum organs and developmental states. It also aims to improve understanding of genetic diversity and allelic richness that might be harbored ex situ (in gene banks) or in situ (in nature), and refine techniques for assesing allelic richness and Expedite data acquisition and utilization by a sound parnership between laboratory scientists and computational biologists. Specific goals of developing physical maps of sorghum and rice genomes include: -Enrich cross-links between sorghum and rice by mapping additional rice probes on sorghum. -Apply mapped DNA probes to macroarrays of sorghum, sugarcane, rice, and maize BACs. -Fingerprint 10x BAC libraries of Sorghum bicolor and S. propinquum. Libraries presently 3x and 6x respectively, to be expanded to 10x each. -Use fragment-matching (BAC-RF) method to determine locus-specificity in polyploids. - Contig assembly based on 1-3, plus rice BAC fingerprints generated under a separate Novartis project. -Evaluate methodology for rapid high-throughput assignment of new ESTs to BACs. -Conduct genomic sequencing in a region duplicated in both sorghum and arabidopsis. Selected BACs from sorghum(2), sugarcane, maize, rice, wheat. By improving the understanding of genetic diversity and allelic richness, the goal is to: -Sequence previously mapped sorghum DNA probes. -Discover & characterize 100 single nucleotide polymorphisms (SNPs) from cDNA markers. -Develop colorimetric high-throughput genotyping assays, and utilize to assess genetic diversity in geographically- and phenotypically-diverse sorghums. -Develop colorimetric high-throughput asssays for identifying phytochrome allelic variation, and apply these assays to a core collection representing a large set of genetic resources. -Support informatics group to streamline cataloging of DNA-level information relevant to large genetic resources collections. Lastly, the goals of expediting data acquisition and utilization include: -A new web-based resource for 3D-integration and visualization of structural and functional genomic data will be developed. -New sequence assembly and alignment software SABER (Sequence AssemBly in the presence of ERror), and PRIMAL(Practical RIgorous Multiple ALignment), will be evaluated with reference to existing standards (PHRED, PHRAP). -Specialized image processing and image analysis tools will be developed for acquistion and interpretation of qualitative and quantitative hybridization signals. To deal expeditiously with large volumes of data, parallel processing approaches will be investigated. Sponsors: * National Science Foundation (NSF) * National Sorghum Producers * University of Georgia Research Foundation (UGARF) * Georgia Research Alliance (GRA)

Proper citation: Comparative Saccharinae Genomics Resource (RRID:SCR_008153) Copy   

•   Source: SciCrunch Registry

http://www.cambridgesoft.com/databases/login/?serviceid=128

THIS RESOURCE IS NO LONGER IN SERVICE,documented on January,18, 2022. ChemBioFinder.com is an online chemistry and biology reference database. With more than 500,000 compounds indexed and linked to other web sites, it provides a wealth of chemical information for professional chemists and students alike. ChemBioFinder.com is the gateway to all databases available from CambridgeSoft.
At ChemBioFinder.com, a subscriber can search for compounds by name, CAS Registry Number, molecular formula or weight, or by structure (exact and substructure). Successful searches return a basic profile of molecules indexed by this site. The profile contains the name, molecular formula and weight, CAS Registry Number, SMILES and InChI strings for each located compound, and lists the databases which contain entries for the located compound(s). Free trials to any of these databases are available, as are annual subscriptions for continuous use of the contents.
Users of ChemBioFinder.com are allowed 5 free searches before we request them to register with us as a cambridgesoft.com website user. The CambridgeSoft user account is free and will give you access to a growing list of products and services which includes, our quarterly print publication Chem & Bio News, frequent webinars, white papers and articles on all our offerings. Set up is fast & easy.
For ChemFinder.com users:
ChemFinder.Com has become ChemBioFinder.Com and has a whole new look and layout. This is part of a gradual redesign of the entire CambridgeSoft website. Here are some of the changes that were made to improve the vital information presented here to the scientific community:
1. Search results show the ChemBioFinder databases which have entries for the compound(s), and indicate the databases to which the logged in user has active subscriptions.
2. There are hyperlinks to the detailed records in the databases with active subscriptions.
3. Search results provide the name, molecular formula and weight, CAS Registry Number, SMILES and InChI strings for the compound.
4. Physical properties are no longer provided unless the user has a subscription to ChemIndex or other CambridgeSoft online databases that provide this information. Many of our products come with one year subscriptions to ChemIndex as part of the package. So you may actually be entitled to a subscription and dont realize it.

Proper citation: ChemBioFinder (RRID:SCR_008180) Copy   

•   Source: SciCrunch Registry

http://www.nimh.nih.gov/funding/clinical-trials-for-researchers/practical/stard/index.shtml

A nationwide public health clinical trial conducted to determine the effectiveness of different treatments for people with major depression, in both primary and specialty care settings, who have not responded to initial treatment with an antidepressant. This is the largest and longest study ever done to evaluate depression treatment. The study is completed and no longer recruiting participants. Each of the four levels of the study tested a different medication or medication combination. The primary goal of each level was to determine if the treatment used during that level could adequately treat participants����?? major depressive disorder (MDD). Those who did not become symptom-free could proceed to the next level of treatment. The design of the STAR*D study reflects what is done in clinical practice because it allowed study participants to choose certain treatment strategies most acceptable to them and limited the randomization of each participant only to his/her range of acceptable treatment strategies. No prior studies have evaluated the different treatment strategies in broadly defined participant groups treated in diverse care settings. Over a seven-year period, the study enrolled 4,041 outpatients, ages 18-75 years, from 41 clinical sites around the country, which included both specialty care settings and primary medical care settings. Participants represented a broad range of ethnic and socioeconomic groups. All participants were diagnosed with MDD, were already seeking care at one of these sites, and were referred to the trial by their doctors. * STAR*D Study Medications: Citalopram (Celexa), Sertraline (Zoloft), Bupropion SR (Wellbutrin SR), Venlafaxine XR (Effexor XR), Buspirone (BuSpar), Mirtazapine (Remeron), Triiodothyronine (T3) (Cytomel), Nortriptyline (Pamelor, Aventyl), Tranylcypromine (Parnate), Lithium (Eskalith, Lithobid) *STAR*D Talk Therapy:Cognitive Therapy

Proper citation: Sequenced Treatment Alternatives to Relieve Depression Study (RRID:SCR_008051) Copy   

•   Source: SciCrunch Registry

http://www.snprc.org/

Center that supports studies of nonhuman primate models of human diseases, including common chronic diseases and infectious diseases and the effects that genetics and the environment have on physiological processes and disease susceptibility. SNPRC encourages the use of its resources by investigators from the national and international biomedical research communities.

Proper citation: Southwest National Primate Research Center (RRID:SCR_008292) Copy   

•   Source: SciCrunch Registry

http://www.dialog.com

Dialog provides critical information from the world''s most authoritative publishers, combined with the tools to search every bit of it with speed and precision. With direct operations in 27 countries, Dialog products and services are a combination of highly accurate online research tools offering access to unique and relevant databases designed to meet the specific needs of a wide range of users. Information professionals and end-users at business, professional, scientific, academic and government organizations in more than 100 countries prize Dialog services to meet their searching needs. As part of the Deep Web, which is estimated to be 500 times larger than the content accessible via Web search engines, Dialog products offer unparalleled depth and breadth of content coupled with the ability to search with precision and speed. Our collection of over 900 databases handles more than 700,000 searches and delivers over 17 million document page views per month. Searchable content on Dialog services includes articles and reports from thousands of real-time news feeds, newspapers, broadcast transcripts and trade publications, plus market research reports and analyst notes providing support for financial decision-making, as well as in-depth repositories of scientific and technical data, patents, trademarks and other intellectual property data. Additional content areas include government regulations, social sciences, food and agriculture, reference, energy and environment, chemicals, pharmaceuticals and medicine.

Proper citation: Dialog (RRID:SCR_008482) Copy   

•   Source: SciCrunch Registry

http://www.amber.org.au/

THIS RESOURCE IS NO LONGER IN SERVICE, documented September 6, 2016. AMBeR's aim is to bring together Australia's unique resources for genetic epidemiology and genomics with high level expertise in bioinformatics and statistical science, conduct advanced methodological research, develop new research capacity and competitiveness in cutting-edge techniques, bring them to bear on important medical research problems, train young Australians in bioinformatics and advanced biostatistics, and transfer this expertise to the medical research community.

Proper citation: Australian Medical Bioinformatics Resource (RRID:SCR_008385) Copy   

•   Source: SciCrunch Registry

http://www.cdc.gov/nccdphp/ace/

A clinical study linking childhood maltreatment and later-life health and well-being. As a collaboration between the Centers for Disease Control and Prevention and Kaiser Permanente''s Health Appraisal Clinic in San Diego, Health Maintenance Organization (HMO) members undergoing a comprehensive physical examination provided detailed information about their childhood experience of abuse, neglect, and family dysfunction. Over 17,000 members chose to participate. To date, over 50 scientific articles have been published and over 100 conference and workshop presentations have been made. Future Directions: The ACE study is now in its 10th year and the prospective phase is currently underway. In this ongoing stage of the study, data are being gathered from various sources including outpatient medical records, pharmacy utilization records, and hospital discharge records to track the subsequent health outcomes and health care use of ACE Study participants. In addition, an examination of National Death Index records will be conducted to establish the relationship between ACE and mortality among the ACE Study population. The ACE Study findings suggest that these experiences are major risk factors for the leading causes of illness and death as well as poor quality of life in the United States. Progress in preventing and recovering from the nation''s worst health and social problems is likely to benefit from the understanding that many of these problems arise as a consequence of adverse childhood experiences. :Sponsors: This resource is supported by the Centers for Disease Control and Prevention and the Kaiser Permanente''s Health Appraisal Clinic in San Diego.

Proper citation: Adverse Childhood Experiences Study (RRID:SCR_008382) Copy   

•   Source: SciCrunch Registry

http://www.broad.mit.edu/cgi-bin/annotation/disease_vector/aedes_aegypti/blast_page.cgi, http://www.broadinstitute.org/cgi-bin/annotation/disease_vector/aedes_aegypti/blast_page.cgi

The goals of this sequencing effort are to produce and publicly release a whole-genome assembly and auto-annotation of the Aedes genome representing 8X sequence coverage. In collaboration, these centers have delivered the target 8X draft coverage of the disease vector genome. Assembly of the genome was performed using the Broad''s whole genome assembly package ARACHNE (Batzoglou et al., 2002 and Jaffe et al., 2003). The Aedes genome will be annotated in a collaborative effort involving both MSCs and Vectorbase, which is a bioinformatics resource center at the University of Notre Dame. Sponsor: This resource is supported by the National Institute of Allergy and Infectious Diseases. Keywords: Genome, BLAST, Similarity, Search, Engine, Sequence, Bioinformatics, Resource,

Proper citation: BLAST Similarity Search (RRID:SCR_008419) Copy   

•   Source: SciCrunch Registry

http://eldermet.ucc.ie

Latest publications: ELDERMET research has recently been published in the Proceedings of the National Academy of Sciences (USA). This work focuses on the composition and stability of the intestinal bacteria in older Irish adults. Read the paper here. Would you like to be part of ELDERMET? We are currently looking for people, aged 65 years or older, living in the community. All we ask is that you live in the Cork area, or are willing to travel to Cork, and have recently (within the last two/three weeks) taken any kind of antibiotic. It doesnt matter if you are still taking the antibiotic, as long as the finishing date isnt more than four weeks before your first visit to ELDERMET. ELDERMET Objectives To assess the composition of the faecal microbiota of elderly volunteers in the Irish population, using state-of-the-art molecular techniques. To correlate diversity, composition, and metabolic potential of the faecal microbial metagenome with health, diet and lifestyle indices that are a) likely to be influenced by the microbiota or b) to influence the microbiota. To develop recommendations for specific dietary ingredients, foodstuffs, functional foods and/or dietary supplements, that will improve the health of elderly consumers. To provide evidence-based recommendations for prospective studies to determine the molecular mechanisms for health improvements promoted by specific food ingredients that modulate components of the microbiota. ELDERMET Rationale The human intestinal microbiota is made up of approximately 1000 genetically unique organisms (phylotypes ) [1]. The bacteria present in the intestine make an important contribution to: metabolism executed in the gut [2] health, in diverse activites from pain perception [3] to cognitive function [4]. There is an increasing body of evidence linking alterations in the human gut microbiota with Inflammatory Bowel Disease [5, 6] and Irritable Bowel Syndrome [7]. The changing pattern of the gut microbiota in elderly subjects [8, 9] may be linked to host changes such as immunosenescence, increased susceptibility to disease and potentially systemic effects. The composition of the intestinal microbiota may be modulated by dietary components including prebiotics [10]. ELDERMET will determine the baseline composition of the gut microbiota of several hundred elderly Irish subjects using a combination of traditional culutre and molecular (culture-independent) methodologies. ELDERMET will explore potential correlations between microbiota composition and a range of health indices; cross-referencing data to dietary intake. Data will be analyzed in the context of the related FHRI projects in Nutrigenomics, Food Consumption, Food Safety, and Diet-Health. ELDERMET will provide recommendations to all stakeholders (including health practitioners and the health service, the food industry and the general public) on how to improve health based on defined modifications to dietary intake. Sponsor. This work is supported by the Goverment of Ireland Department of Agriculture Fisheries and Food/Health Research Board Food for Health Research Initiative award to the ELDERMET project as well as by a Science Foundation Ireland award to the Alimentary Pharmabiotic Centre. M.J.C. is now funded by a fellowship from the Health Research Board of Ireland.

Proper citation: ELDERMET Gut microbiota as an indicator and agent of nutritional health in elderly Irish subjects (RRID:SCR_008492) Copy   

•   Source: SciCrunch Registry

http://www.jneurosci.org/supplemental/18/12/4570/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on January 29, 2013. Supplemental data for the paper Changes in mitochondrial function resulting from synaptic activity in the rat hippocampal slice, by Vytautas P. Bindokas, Chong C. Lee, William F. Colmers, and Richard J. Miller that appears in the Journal of Neuroscience June 15, 1998. You can view digital movies of changes in fluorescence intensity by clicking on the title of interest.

Proper citation: Hippocampal Slice Wave Animations (RRID:SCR_008372) Copy   

•   Source: SciCrunch Registry

http://cgems.cancer.gov

The project began as a pilot study to identify inherited genetic susceptibility to prostate and breast cancer. CGEMS has developed into a robust research program involving genome-wide association studies (GWASs) for a number of cancers to identify common genetic variants that affect a person''s risk of developing cancer. In collaboration with extramural scientists, NCI''s Division of Cancer Epidemiology and Genetics (DCEG) has carried out genome-wide scans for breast, prostate, pancreatic, and lung cancers, while a GWAS of bladder cancer is currently underway. By making the data available to both intramural and extramural research scientists, as well as those in the private sector through rapid posting, NIH can leverage its resources to ensure that the dramatic advances in genomics are incorporated into rigorous population-based studies. Ultimately, findings from these studies may yield new preventive, diagnostic, and therapeutic interventions for cancer. Sponsors: This resource is supported by the U.S. National Institues Of Health.

Proper citation: CGEMS (RRID:SCR_008445) Copy   

•   Source: SciCrunch Registry

http://www.lexisnexis.com

A commercial software provider designed for legal, risk management, corporate, government, law enforcement, accounting, and academic markets. Sponsors: This resource is Reed Elsevier, Inc. Keywords: Workflow, Professional, Legal, Risk, Management, Corporate, Government, Law, Enforcement, Accounting, Academic, Technology, Information,

Proper citation: LexisNexis (RRID:SCR_008433) Copy   

•   Source: SciCrunch Registry

http://www.track-hd.net

TRACK-HD is a multi-centermulti-national prospective, observational biomarker study of premanifest and early stage HD with no experimental treatment. Objectives: - determine what combination of measures is the most sensitive for detecting change over the natural course of premanifest and early HD - to validate these as potential outcome measures for use in future therapeutic trials Design: - focused on intensive battery of novel assessments - extensive annual assessments - dynamic and fluid protocol - robust evidence-based measures TRACK-HD is a major new international study of Huntingtons disease. It aims to be the most comprehensive study of premanifest and early HD, and will define the best combination of assessments to be used in clinical trials of disease-modifying treatments in HD. TRACK-HD began in January 2008 and involves 360 subjects at 4 sites internationally. Sponsors: This resource is supported by The UK Medical Research Council (MRC), CHDI Foundation, Inc., The Euro-HD Network, The Wellcome Trust, The Department of Health, The Huntingtons Disease Association, and The Brain Research Trust. Keywords: Biomarker, Experimental, Treatment, Research, Therapeutic, Trail, Hunginton''s, Disease, Health,

Proper citation: Track-HD (RRID:SCR_008397) Copy   

•   Source: SciCrunch Registry

http://salilab.org/modeller/modeller.html

Software tool as Program for Comparative Protein Structure Modelling by Satisfaction of Spatial Restraints. Used for homology or comparative modeling of protein three dimensional structures. User provides alignment of sequence to be modeled with known related structures and MODELLER automatically calculates model containing all non hydrogen atoms.

Proper citation: MODELLER (RRID:SCR_008395) Copy   

•   Source: SciCrunch Registry

http://www.fa-petition.org/en/attivita/progetti2008.html

The aim of this resource is to facilitate and promote, even through fund-raising, the scientific research for the treatment of Friederich''s Ataxia. The mission of this portal is to: - To distribute information to the people affected by the disease and to make the general population aware. - Promote, fund and support the diagnosis, research, cure and potential treatments. - Promote the cooperation with other voluntary associations both national and international. Sponsors: This resource is supported by the RUDI Committee. Keywords: Research, Diagnosis, Cure, Treatment, Disease, Scientific, Friederich''s Ataxia,

Proper citation: ATASSIA DI FRIEDREICH - PROGETTI 2006 (RRID:SCR_008391) Copy   

•   Source: SciCrunch Registry

http://amser.org./index.php?P=AMSER--About

AMSER is a portal of educational resources and services built specifically for use by those in Community and Technical Colleges but free for anyone to use. AMSER provides links to resources for faculty, staff, librarians, students and others for use in both educational settings or in their pursuit of life long learning. Sponsors: AMSER is funded by the National Science Foundation (NSF) as part of the National Science Digital Library, and is being created by a team of project partners led by Internet Scout.

Proper citation: Applied Math and Science Education Repository (RRID:SCR_008501) Copy   

•   Source: SciCrunch Registry

http://www.cff.org/treatments/Pipeline/

The Cystic Fibrosis Foundation has built a dynamic pipeline for the development of more new potential cystic fibrosis (CF) therapies than ever before. To treat a complex disease like CF, therapies must target problems in the airways and the digestive system. In the CF drug development pipeline, there also are promising new therapies designed to rectify the cause of CF a faulty gene and/or its faulty protein product. Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States (70,000 worldwide). A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that: clogs the lungs and leads to life-threatening lung infections; and obstructs the pancreas and stops natural enzymes from helping the body break down and absorb food. In the 1950s, few children with cystic fibrosis lived to attend elementary school. Today, advances in research and medical treatments have further enhanced and extended life for children and adults with CF. Many people with the disease can now expect to live into their 30s, 40s and beyond.

Proper citation: Drug Development Pipeline (RRID:SCR_008464) Copy   

•   Source: SciCrunch Registry